LifeSciences BC is governed by a Board of Directors, whose members represent British Columbia’s biotechnology, medical devices, bioproducts, bioenergy and greater life sciences community. Our Board provides guidance, sets policy and ensures that the organization operates effectively in achieving its mandate, which is to facilitate a strong commercial economic development of the biotechnology and life sciences industry in B.C.
As of our September 20, 2012 Annual General Meeting, the following individuals will comprise LifeSciences BC's Board:
Gordon McCauley - President and CEO, Allon Therapeutics
Ian Heine - Partner, PwC
Joe Garcia - Partner, Blake, Cassels & Graydon LLP
Dr. Simon Pimstone - President and CEO, Xenon Pharmaceuticals
David Hall - CEO, President and Director, RepliCel Life Sciences
Hector MacKay-Dunn, QC - Senior Partner, Farris, Vaughan, Wills & Murphy LLP
Paul Geyer - CEO, LightIntegra Technology
Dr. Ali Tehrani - President and CEO, Zymeworks Inc.
Dr. Alan Winter - President and CEO, Genome British Columbia
Robin Ciceri - President, The Research Universities' Council of BC
Nancy Harrison - Chief Business Officer, MSI Methylation Sciences Inc.
Dr. Gavin Stuart - Dean, Faculty of Medicine, University of British Columbia